Trial of Hemophilia B Gene Therapy BBM-H901 Begins Dosing in China

Trial of Hemophilia B Gene Therapy BBM-H901 Begins Dosing in China

315579

Trial of Hemophilia B Gene Therapy BBM-H901 Begins Dosing in China

The first man with hemophilia B has been dosed in a clinical trial in China to evaluate Belief BioMed’s investigational one-time gene therapy BBM-H901. According to the company, BBM-H901 is the first investigational gene therapy given intravenously, or directly into a vein, for hemophilia B or any genetic disease to enter clinical testing. “We are thankful to our clinical collaborators, our patient community and our entire team who made this happen,” Xiao Xiao, co-founder, chairman,…

You must be logged in to read/download the full post.